OBJECTIVE: Thymic carcinomas are considered to be more aggressive than thymomas and carry a worse prognosis. We reviewed our recent experience with the surgical management of thymic tumors and compared the outcomes and patterns of relapse between patients with thymic carcinoma and those with thymoma. METHODS: We performed a single-institution retrospective cohort study. Data included patient demographics, stage, treatment, pathologic findings, and postoperative outcomes. RESULTS: During the period 1995-2006, 120 patients with thymic tumors underwent surgical intervention, including 23 patients with thymic carcinoma and 97 patients with thymoma, as classified according to the World Health Organization 2004 histologic classification. The overall 5-year survival was significantly different between patients with thymic carcinoma and those with thymoma (thymic carcinoma, 53%; thymoma, 89%; P = .01). Data on relapse were available for 112 patients. The progression-free 5-year survival was also significantly different between patients with thymic carcinoma and those with thymoma (thymic carcinoma, 36%; thymoma, 75%; P < .01). Using multivariate analysis, thymic carcinoma and incomplete resection were found to be independent predictors of progression-free survival. Relapses in patients with thymic carcinoma tended to occur earlier, and occurred significantly more frequently at distant sites than in patients with thymoma (60% vs 13%, P = .01). CONCLUSIONS: Patterns of relapse differ significantly between patients with thymic carcinoma and those with thymoma, with lower progression-free survival, earlier onset, and more distant relapses in patients with thymic carcinoma. Given the greater propensity for distant failures, the inclusion of systemic therapy in the treatment of thymic carcinoma might take on greater importance. Despite significantly higher rates of distant relapse, good overall survival in patients with thymic carcinoma can be achieved.
OBJECTIVE:Thymic carcinomas are considered to be more aggressive than thymomas and carry a worse prognosis. We reviewed our recent experience with the surgical management of thymic tumors and compared the outcomes and patterns of relapse between patients with thymic carcinoma and those with thymoma. METHODS: We performed a single-institution retrospective cohort study. Data included patient demographics, stage, treatment, pathologic findings, and postoperative outcomes. RESULTS: During the period 1995-2006, 120 patients with thymic tumors underwent surgical intervention, including 23 patients with thymic carcinoma and 97 patients with thymoma, as classified according to the World Health Organization 2004 histologic classification. The overall 5-year survival was significantly different between patients with thymic carcinoma and those with thymoma (thymic carcinoma, 53%; thymoma, 89%; P = .01). Data on relapse were available for 112 patients. The progression-free 5-year survival was also significantly different between patients with thymic carcinoma and those with thymoma (thymic carcinoma, 36%; thymoma, 75%; P < .01). Using multivariate analysis, thymic carcinoma and incomplete resection were found to be independent predictors of progression-free survival. Relapses in patients with thymic carcinoma tended to occur earlier, and occurred significantly more frequently at distant sites than in patients with thymoma (60% vs 13%, P = .01). CONCLUSIONS: Patterns of relapse differ significantly between patients with thymic carcinoma and those with thymoma, with lower progression-free survival, earlier onset, and more distant relapses in patients with thymic carcinoma. Given the greater propensity for distant failures, the inclusion of systemic therapy in the treatment of thymic carcinoma might take on greater importance. Despite significantly higher rates of distant relapse, good overall survival in patients with thymic carcinoma can be achieved.
Authors: Philipp Ströbel; Martina Hartmann; Andreas Jakob; Kristina Mikesch; Ingo Brink; Stefan Dirnhofer; Alexander Marx Journal: N Engl J Med Date: 2004-06-17 Impact factor: 91.245
Authors: E Ruffini; M Mancuso; A Oliaro; C Casadio; A Cavallo; R Cianci; P L Filosso; M Molinatti; C Porrello; N Cappello; G Maggi Journal: J Thorac Cardiovasc Surg Date: 1997-01 Impact factor: 5.209
Authors: Philipp Ströbel; Andrea Bauer; Bernhard Puppe; Til Kraushaar; Axel Krein; Klaus Toyka; Ralf Gold; Michael Semik; Reinhard Kiefer; Wilfred Nix; Berthold Schalke; Hans Konrad Müller-Hermelink; Alexander Marx Journal: J Clin Oncol Date: 2004-04-15 Impact factor: 44.544
Authors: D Blumberg; J L Port; B Weksler; R Delgado; J Rosai; M S Bains; R J Ginsberg; N Martini; P M McCormack; V Rusch Journal: Ann Thorac Surg Date: 1995-10 Impact factor: 4.330
Authors: Tony Y Eng; Clifton D Fuller; Jaishree Jagirdar; Yadvindera Bains; Charles R Thomas Journal: Int J Radiat Oncol Biol Phys Date: 2004-07-01 Impact factor: 7.038
Authors: Anya M Litvak; Kaitlin Woo; Sara Hayes; James Huang; Andreas Rimner; Camelia S Sima; Andre L Moreira; Maria Tsukazan; Gregory J Riely Journal: J Thorac Oncol Date: 2014-12 Impact factor: 15.609
Authors: Dwight Owen; Benjamin Chu; Amy M Lehman; Lakshmanan Annamalai; Jennifer H Yearley; Konstantin Shilo; Gregory A Otterson Journal: J Thorac Oncol Date: 2018-04-24 Impact factor: 15.609
Authors: Ankit Modh; Andreas Rimner; Pamela K Allen; Brad Greenfield; Edith M Marom; David Rice; James Huang; Kenneth E Rosenzweig; Ritsuko Komaki; Daniel R Gomez Journal: Am J Clin Oncol Date: 2016-04 Impact factor: 2.339
Authors: Vincent Thomas de Montpréville; Maria-Rosa Ghigna; Ludovic Lacroix; Benjamin Besse; Philippe Broet; Philippe Dartevelle; Elie Fadel; Peter Dorfmuller Journal: Virchows Arch Date: 2013-01-15 Impact factor: 4.064